News
LASAM Opposes Classifying Mifepristone as a Controlled Substance
On May 17th, Louisiana Society of Addiction Medicine (LASAM) sent a letter of opposition to SB 276 ahead of its consideration by the Louisiana House of Representatives. SB 276 would designate mifepristone as a controlled substance.
LASAM emphasized its opposition to legislative interference into the patient-clinician relationship within the realm of reproductive healthcare. LASAM also characterized SB 276 as a misuse of the drug scheduling system, noting that mifepristone has been safely used in healthcare for decades. Finally, LASAM expressed concern that the enactment of SB 276 would enhance stigma against pregnant patients with substance use disorder (SUD). LASAM clarified that pregnant patients experience numerous obstacles to accessing evidence-based care for their condition. SB 276 would only increase confusion and stigma for pregnant patients.